We are delighted to announce Dr Arno Bourgonje as a touchIMMUNOLOGY Future Leader 2026, selected by peers as one of the immunologists changing the future of gastroenterology care.
Dr Arno Bourgonje is currently affiliated with the University Medical Center Groningen and the Icahn School of Medicine at Mount Sinai, where he works as a phsyician-scientist in gastroenterology and immunology. His research focuses on identifying and applying novel biomarker signatures in inflammatory bowel diseases to improve disease prediction, diagnosis, and treatment outcomes, building on a PhD completed cum laude at the University of Groningen. Dr Arno Bourgonje’s work has identified new biomarker panels associated with disease severity, treatment response, and complications in inflammatory bowel disease.
In this Q&A, Dr Bourgonje discusses what drew him to a career in gastroenterology, a defining breakthrough in his research that influenced the field, and the current innovations in inflammatory bowel disease that excite him most.
New insights are added regularly, covering a broad range of subspecialties and evolving clinical scenarios. Sign up below for Free Access to the latest clinical updates in your specialty!
What inspired you to pursue a career in gastroenterology?
What initially attracted me to gastroenterology was the strong interplay between immunology, microbiology and clinical medicine. Inflammatory bowel diseases (IBDs) in particular are highly complex disorders in which genetics, the immune system, environmental exposures and the microbiome all interact over many years before disease onset. I have always found it fascinating that by studying these mechanisms, we can not only better understand disease biology, but also directly improve patient care. The combination of translational research, rapidly evolving therapies and long-term patient relationships made gastroenterology a very natural fit for me.
Can you share a defining breakthrough in your research and how it impacted your field?
A defining focus of my research has been the application of high-throughput serological technologies, including PhIP-Seq, to study preclinical immune responses in IBD. By analysing longitudinal serum samples collected years before diagnosis, we and others have shown that systemic immune alterations may already be detectable long before clinical disease becomes apparent. I believe these findings are important because they shift the perspective of IBD from a disease that suddenly develops at diagnosis towards a slowly evolving process with a prolonged preclinical phase. This may ultimately open new avenues for early detection, risk stratification and preventive strategies.
What current innovations in inflammatory bowel disease excite you the most?
One of the most exciting developments is the convergence of multi-omics technologies with artificial intelligence and longitudinal patient cohorts. We are increasingly becoming better in integrating immunological, microbial, genetic and clinical data at unprecedented scale. I think this will fundamentally transform how we understand disease heterogeneity and treatment response in IBD. In parallel, the rapid expansion of targeted therapies, including selective cytokine inhibition and pathway-specific treatments, is moving the field closer to personalized medicine. I am particularly excited by approaches that combine biomarker-driven patient stratification with precision therapeutic monitoring.
More content in inflammatory bowel disease.
Cite: Dr Arno Bourgonje on advancing biomarker discovery to transform IBD care: touchIMMUNOLOGY Future Leaders 2026. touchIMMUNOLOGY. 21 May 2026.
Disclosures: This short article was prepared by touchIMMUNOLOGY in collaboration with Dr Bourgonje. No fees or funding were associated with its publication.
